MDXG · Mimedx Group, Inc. · Financials
10 customers — 22% of revenue (the year ended December 31, 2025)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 1% of revenue (the year ended December 31, 2025)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
10 customers — 20% of revenue (the year ended December 31, 2024)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 1% of revenue (the year ended December 31, 2024)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
10 customers — 20% of revenue (the year ended December 31, 2023)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 2% of revenue (the year ended December 31, 2023)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2027 (G) | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $400M | $260M – $290M | $355.17M | $418.63M | $348.88M | $321.48M | $267.84MG | $242.02MG | $248.23M | $299.26M | $359.11M | $321.14M | $221.71M | — | — | — | — | $7.76M | $788.87K | |
| — | — | -$6.59M | — | — | -$6.46M | -$5.02M | -$4.98M | -$7.94M | -$4.71M | $527K | -$87K | -$339K | — | — | — | — | — | — | |
| — | — | $75.12M | $73.01M | $60.07M | $54.63M | $48.32M | $39.63M | $39.33M | $43.08M | $36.39M | $35.22M | $30.94M | $20.2M | $12.67M | $9.33M | $5.19M | $3.36M | $1.72M | |
| — | — | $280.05M | $345.62M | $288.81M | $266.84M | $219.53M | $202.39M | $208.9M | $256.17M | $322.73M | $285.92M | $190.77M | $167.09M | $105.56M | $49.85M | $21.87M | $4.4M | — | |
| — | — | — | 82.56% | 82.78% | 83.01% | 81.96% | 83.63% | 84.16% | 85.6% | 89.87% | 89.03% | 86.05% | — | — | — | — | 56.73% | — | |
| — | — | $15.38M | $15.1M | $12.34M | $12.67M | $12.7M | $9.93M | $11.72M | $11.14M | $15.77M | $17.9M | $14.34M | $8.41M | $7.05M | $4.84M | $2.89M | $2.98M | $2.75M | |
| — | — | $206.73M | $209.68M | $175.56M | $161.83M | $151.23M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $52.72M | $56.51M | $49.53M | $49.29M | $57.45M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $255.08M | $266.19M | $225.09M | $211.12M | $208.67M | $194.85M | $181.02M | $198.21M | $258.53M | $220.12M | $173.41M | $133.38M | $90.48M | $46.23M | $19.59M | $9.85M | $6.85M | |
| — | — | $832K | $439K | $765K | $762K | $701K | $820K | $1.07M | $1.04M | $1.03M | $1.68M | $2.14M | $933K | $928K | $1.05M | $1.38M | $1.34M | $667.93K | |
| — | — | — | $14.88M | $6.04M | $3.43M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | $0 | $0 | $8.54M | $6.06M | — | — | — | — | — | — | — | — | |
| — | — | $8.75M | $63.89M | $58.87M | $37.12M | -$14.73M | -$7.05M | -$45.4M | -$21.16M | -$3.92M | $46.22M | $884K | $24.36M | $7.1M | -$2.64M | -$5.36M | -$9.76M | -$10.53M | |
| — | — | — | 15.26% | 16.87% | 11.55% | -5.5% | -2.91% | -18.29% | -7.07% | -1.09% | 14.39% | 0.4% | — | — | — | — | -125.78% | -1335.15% | |
| — | — | — | $78.77M | $64.91M | $40.54M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $1.71M | $1.78M | $3.94M | $6.58M | $5.05M | — | — | — | — | — | $339K | $86K | $48K | $45K | $593K | $117.82K | $599.65K | |
| — | — | $5.02M | $4.72M | $2.93M | $118K | $32K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$582K | -$558K | -$565K | -$26K | -$4000 | -$23K | -$3000 | $283K | $0 | $0 | -$339K | — | — | — | — | — | — | |
| — | — | $11.53M | $66.26M | $57.29M | $30.63M | -$19.75M | -$12.05M | -$61.54M | -$25.59M | -$3.4M | $45.09M | $545K | $24.28M | $7.05M | -$4.01M | -$7.66M | -$10.19M | -$11.42M | |
| — | — | $5.3M | $17.68M | $15.3M | -$36.81M | $206K | $247K | -$12.26M | -$5000 | $26.58M | -$19.64M | $155K | -$5.17M | $832K | $100K | $0 | $0 | $0 | |
| — | — | $6.24M | $48.58M | $42.42M | $58.23M | -$30.2M | -$10.29M | -$49.28M | -$25.58M | -$29.98M | $64.73M | $390K | $29.45M | $6.22M | -$4.11M | -$7.66M | -$10.19M | -$11.42M | |
| — | — | — | 11.6% | 12.16% | 18.11% | -11.27% | -4.25% | -19.85% | -8.55% | -8.35% | 20.16% | 0.18% | — | — | — | — | -131.36% | -1447.6% | |
| — | — | -$2.54M | — | — | — | -$36.78M | -$16.42M | -$83.33M | -$25.58M | -$29.98M | — | — | — | — | — | — | — | — | |
| USD/shares | — | — | $0.04 | $0.33 | $0.29 | $0.40 | -$0.33 | -$0.15 | -$0.77 | -$0.24 | -$0.28 | $0.61 | $0.00 | $0.28 | $0.06 | -$0.04 | -$0.09 | — | — |
| USD/shares | — | — | $0.04 | $0.32 | $0.28 | $0.37 | -$0.33 | -$0.15 | -$0.77 | -$0.24 | -$0.28 | $0.56 | $0.00 | $0.26 | $0.05 | -$0.04 | -$0.09 | — | — |
| shares | — | — | — | 147.79M | 146.98M | 116.5M | 112.91M | 110.35M | 108.26M | 106.95M | 105.6M | 106.12M | 105.93M | 105.93M | 105.79M | 96.29M | 81.65M | 72.45M | — |
| shares | — | — | — | 149.72M | 149.05M | 145.96M | 112.91M | 110.35M | 108.26M | 106.95M | 105.6M | 116.11M | 112.65M | 113.63M | 113.3M | 96.29M | 81.65M | 72.45M | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2025: $136.86M in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of long-term debt | 2026-06-30 | USD 1,500,000 | 10-Q filed 2026-07-29 |
| Noncurrent debt carrying amount | 2026-06-30 | USD 15,706,000 | 10-Q filed 2026-07-29 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 308 similar-size Biotechnology companies (of 559 listed).
EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.
Valuation over time computed as of each quarter's filing date
EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Wound Surgical Segment | $264,906,000 | $238,940,000 | $213,489,000 |
| Regenerative Medicine Segment | $0 | $16,596,000 | $32,362,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Wound | $276,326,000 | $231,004,000 | $205,660,000 | $175,970,000 | — | — |
| Surgical | $142,304,000 | $117,875,000 | $115,817,000 | $91,871,000 | — | — |
| Advanced Wound Care Tissue and Other | — | — | — | $241,992,000 | — | $192,566,000 |
| Advanced Wound Care Umbilical Cord Derived | — | — | — | $23,211,000 | — | $16,073,000 |
| Hospital Site of Service | — | — | — | $163,206,000 | $142,140,000 | $144,285,000 |
| Other Site of Service | — | — | — | $27,477,000 | $25,357,000 | $28,311,000 |
| Private Office Site of Service | — | — | — | $77,158,000 | $74,522,000 | $75,638,000 |
| Section 351 | — | — | — | $2,379,000 | — | $31,828,000 |
| Product And Service Other | — | — | — | $259,000 | — | $7,767,000 |